Side-by-side · Research reference
CartalaxvsTeriparatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BFDA-ApprovedHUMAN-REVIEWED10/62 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
Teriparatide
PTH (1-34) Fragment · FDA-Approved
SQ · Thigh/Abdomen · Once Daily
01Mechanism of Action
Parameter
Cartalax
Teriparatide
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites
Feedback intact?
—
Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Teriparatide
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
RCT / FDA-approved
Standard dose (osteoporosis)
—
20 mcg / day
FDA-approved regimen for severe osteoporosis.
Frequency
—
Once daily
Intermittent administration preserves anabolic effect.
Maximum duration
—
24 months lifetime
Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.
Hypoparathyroidism dose
—
20 mcg / day
Used off-label for chronic hypoparathyroidism.
Pelvic fragility fractures
—
20 mcg / day × 8-12 weeks
Accelerates fracture healing; reduces time to union.Crooks 2026
Route
—
Subcutaneous (thigh or abdomen)
Timing
—
Morning or evening (flexible)
Storage
—
Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use
Pharmacogenetics
—
ALDH2 polymorphisms may influence BMD responseObara 2026
ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Teriparatide
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
Fat loss application
—
None — teriparatide is a bone anabolic agent without direct lipolytic activity
04Side Effects & Safety
Parameter
Cartalax
Teriparatide
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Hypercalcemia
—
Transient serum calcium elevation 4-6 hours post-injection
Monitor serum calcium; usually asymptomatic.
Orthostatic hypotension
—
Dizziness, lightheadedness within hours of injection
Nausea
—
Common, usually mild and transient
Leg cramps / Arthralgia
—
Musculoskeletal pain reported in clinical trials
Hypercalciuria
—
Increased urinary calcium excretion; monitor for nephrolithiasis risk
Osteosarcoma (black box warning)
—
Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation
Injection site reaction
—
Erythema, bruising, pain (uncommon)
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Teriparatide
- ·Paget's disease of bone (increased baseline osteosarcoma risk)
- ·Unexplained elevated alkaline phosphatase
- ·Prior skeletal radiation therapy
- ·Skeletal malignancies or bone metastases
- ·Hypercalcemic disorders (primary hyperparathyroidism)
- ·Pregnancy / lactation
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Teriparatide
- ·Active or recent nephrolithiasis
- ·Severe renal impairment (CKD G4-G5)
- ·Hypercalciuria without adequate monitoring
05Administration Protocol
Parameter
Cartalax
Teriparatide
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.
4. Injection technique
—
Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.
5. Monitoring
—
Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.
6. Calcium and vitamin D supplementation
—
Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.